<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522377</url>
  </required_header>
  <id_info>
    <org_study_id>Ketamine ECT</org_study_id>
    <nct_id>NCT02522377</nct_id>
  </id_info>
  <brief_title>Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression</brief_title>
  <official_title>Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proof of concept study, the investigators plan to administer iv ketamine interleaved
      with ECT days.

      Patients with treatment resistant depression who are deemed to be eligible for ECT treatment
      will randomly be assigned to either ketamine or active placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare the effects of standard ketamine dosing with an active placebo arm.

      Hypothesis 1:

      The investigators hypothesize that interleaved Electroconvulsive Treatment and active
      ketamine treatment will lead to a meaningful clinical improvement compared to
      Electroconvulsive Treatment and placebo treatment arm.

      Hypothesis 2:

      The investigators hypothesize that interleaved Electroconvulsive Treatment and active
      ketamine treatment will attenuate cognitive side effects.

      Methods and Design:

      Patients with treatment resistant depression who are deemed to be eligible for
      Electroconvulsive Treatment will randomly be assigned to either ketamine or active placebo

      Electroconvulsive Treatments:

      All patients (independent of their depression scores) will receive the same Electroconvulsive
      Treatment parameters: Bi-frontal brief pulse (0.5 miliseconds) Electroconvulsive Treatment
      administered by using Thymatron Electroconvulsive Treatment machine.

      Study blinding:

      Neither the patients, nor the treating psychiatrist or the nurse will be aware of the
      patient's assigned arm. The success of blinding will be tested after each ketamine treatment
      with a questionnaire given to the subject, raters, and treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD-17) at Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>Change in HAMD-17 at Infusion 6. Scores range from 0 to 50, with higher scores representing more depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS) at Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MOCA) at Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>MoCA scores range between 0 and 30. Higher scores reflect higher cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test - Revised (HVLT-R) at Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>The number of words remembered are recorded. Scores range from 0 to 12 with higher scores reflecting better acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Oral Word Association Test (COWAT) at Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>This is a verbal fluency measure. Outcome is the count of words that meet criteria within 1 minute, so the minimum is 0 and no fixed maximum exists. Higher scores reflect a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate on HAMD-17 by Last Infusion</measure>
    <time_frame>visit 17</time_frame>
    <description>Count of the patients who showed response (&gt;50% decrease).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Severe Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine Infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>inter venous injections</description>
    <arm_group_label>Ketamine Infusions</arm_group_label>
    <other_name>Ketalar</other_name>
    <other_name>Calypsol</other_name>
    <other_name>Ketanest</other_name>
    <other_name>Tekam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>inter venous injections</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Dormicum</other_name>
    <other_name>Hypnovel</other_name>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males/females at least 18 years of age but no older than 65 years of age

          2. Meet Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV)
             criteria for Major Depression or Bipolar Disorder, depressed phase, as determined by a
             clinician's diagnostic evaluation and confirmed by interview using the Mini
             International Neuropsychiatric Interview (MINI PLUS 5.0.0)

          3. A current depressive episode that has lasted a minimum of 4 weeks.

          4. Have &gt; 3 trials of antidepressants/augmentation strategies.

          5. Have a support system capable of transporting the patient post-treatment.

        Exclusion Criteria:

          1. Meeting Diagnostic and Statistical Manual of Mental Disorders criteria for
             schizophrenia, schizophreniform disorder, schizoaffective disorder, mental
             retardation, pervasive developmental disorder.

          2. Meeting Diagnostic and Statistical Manual of Mental Disorders criteria for other
             substance/alcohol dependence within the past 6 months or abuse in the past 3 months.

          3. Patients who meet exclusion criteria for ketamine and/or midazolam infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Altinay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation Center for Behavioral Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <results_first_submitted>June 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 29, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Dr. Murat Altinay</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Electroconvulsive Therapy</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>electroconvulsive treatment</keyword>
  <keyword>Severe depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02522377/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with TRD who are admitted to the inpatient psychiatric to receive an acute series of ECT will randomly be assigned to one of the study arms.</recruitment_details>
      <pre_assignment_details>15 patients with TRD, who were referred to the Cleveland Clinic outpatient depression clinic or ECT service, were recruited in the study. 3 subjects were lost prior to randomization. 2 subjects were lost to follow up after the screening visit, and 1 subject withdrew consent after the baseline visit.12 patients were included in the final analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine Infusions</title>
          <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Remission Achieved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine Infusions</title>
          <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="11.9"/>
                    <measurement group_id="B2" value="37.6" spread="15.5"/>
                    <measurement group_id="B3" value="38.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HAMD-17) at Last Infusion</title>
        <description>Change in HAMD-17 at Infusion 6. Scores range from 0 to 50, with higher scores representing more depression.</description>
        <time_frame>visit 17</time_frame>
        <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAMD-17) at Last Infusion</title>
          <description>Change in HAMD-17 at Infusion 6. Scores range from 0 to 50, with higher scores representing more depression.</description>
          <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.74" spread="2.62"/>
                    <measurement group_id="O2" value="14.97" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority test based upon group differences pooled across infusions</non_inferiority_desc>
            <p_value>0.72</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes main effect for treatment group and infusion number categorically. Satterthwaite DF=9.987.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.28</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Midazolam - Ketamine Infusions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS) at Last Infusion</title>
        <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60</description>
        <time_frame>visit 17</time_frame>
        <population>Analysis was performed using mixed effect models. Maximum likelihood estimation allowed inclusion of all patients in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS) at Last Infusion</title>
          <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60</description>
          <population>Analysis was performed using mixed effect models. Maximum likelihood estimation allowed inclusion of all patients in analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.29" spread="4.52"/>
                    <measurement group_id="O2" value="24.27" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority test based upon group differences pooled across infusions in mixed effect model</non_inferiority_desc>
            <p_value>0.77</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes main effect for treatment group and infusion number categorically. Satterthwaite DF=7.836.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.40</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Midazolam - Ketamine Infusions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MOCA) at Last Infusion</title>
        <description>MoCA scores range between 0 and 30. Higher scores reflect higher cognition.</description>
        <time_frame>visit 17</time_frame>
        <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MOCA) at Last Infusion</title>
          <description>MoCA scores range between 0 and 30. Higher scores reflect higher cognition.</description>
          <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.81" spread="0.96"/>
                    <measurement group_id="O2" value="25.79" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority test based upon group differences pooled across infusions</non_inferiority_desc>
            <p_value>0.40</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes main effect for treatment group and infusion number categorically. Satterthwaite DF=9.987.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Midazolam - Ketamine Infusions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hopkins Verbal Learning Test - Revised (HVLT-R) at Last Infusion</title>
        <description>The number of words remembered are recorded. Scores range from 0 to 12 with higher scores reflecting better acquisition.</description>
        <time_frame>visit 17</time_frame>
        <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Hopkins Verbal Learning Test - Revised (HVLT-R) at Last Infusion</title>
          <description>The number of words remembered are recorded. Scores range from 0 to 12 with higher scores reflecting better acquisition.</description>
          <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="0.56"/>
                    <measurement group_id="O2" value="11.20" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority test based upon group differences pooled across infusions</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes main effect for treatment group and infusion number categorically. Satterthwaite DF=9.3634.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Midazolam - Ketamine Infusions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Controlled Oral Word Association Test (COWAT) at Last Infusion</title>
        <description>This is a verbal fluency measure. Outcome is the count of words that meet criteria within 1 minute, so the minimum is 0 and no fixed maximum exists. Higher scores reflect a better outcome.</description>
        <time_frame>visit 17</time_frame>
        <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Controlled Oral Word Association Test (COWAT) at Last Infusion</title>
          <description>This is a verbal fluency measure. Outcome is the count of words that meet criteria within 1 minute, so the minimum is 0 and no fixed maximum exists. Higher scores reflect a better outcome.</description>
          <population>Analysis was performed on all patients using a mixed effect model. Maximum likelihood estimation allowed for inclusion of all patients, even when loss to follow-up or remission occurred.</population>
          <units>number of words</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.45" spread="2.83"/>
                    <measurement group_id="O2" value="37.17" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority test based upon group differences pooled across infusions</non_inferiority_desc>
            <p_value>0.34</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes main effect for treatment group and infusion number categorically. Satterthwaite DF=9.987.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.71</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Midazolam - Ketamine Infusions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate on HAMD-17 by Last Infusion</title>
        <description>Count of the patients who showed response (&gt;50% decrease).</description>
        <time_frame>visit 17</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusions</title>
            <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate on HAMD-17 by Last Infusion</title>
          <description>Count of the patients who showed response (&gt;50% decrease).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>7.20</ci_upper_limit>
            <estimate_desc>Odds Ratio of Midazolam (numerator) to Ketamine Infusions (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine Infusions</title>
          <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine alternated with Electroconvulsive Treatments.
Ketamine: intervenous injections</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
Midazolam: intervenous injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Thoughts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MURAT ALTINAY, MD</name_or_title>
      <organization>CLEVELAND CLINIC FOUNDATION</organization>
      <phone>2164453359</phone>
      <email>altinam@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

